

BSP Antibigram 2024																
GRAM NEGATIVE	ANTIBIOTICS															
1/1/2024-12/31/2024	Number tested	Amoxicillin/Clavulanic Acid	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin ^(a)	Levofloxacin	Meropenem	Nitrofurantoin	Piperacillin/Tazobactam	Tetracycline	Tobramycin	Trimeth/Sulfa
ORGANISM	PERCENT SUSCEPTIBLE															
Enterobacter cloacae complex	56	•		•	93	•	93		96	95	96	23	•			91
Escherichia coli	929	84		82	93	90	69	#	93	71	100	94	97			78
Klebsiella pneumoniae	238	89		89	91	90	83	#	96	85	100	24	93			87
Proteus mirabilis	121	88		92	98	98	73	#	92	73	100	0	100			81
Pseudomonas aeruginosa	133				89		82			80	91		91			

GRAM POSITIVE	ANTIBIOTICS											
1/1/2024-12/31/2024	Number tested	Ampicillin	Clindamycin	Erythromycin	Gentamycin (High-Level)	Linezolid	Nitrofurantoin	Oxacillin	Streptomycin (High-Level)	Tetracycline	Trimeth/Sulfa	Vancomycin
Organism	PERCENT SUSCEPTIBLE											
Enterococcus faecalis	156	99		10	76	100	99		92	26		99
Staphylococcus aureus, ALL	199		74	50		100		62		89	88	100
MRSA only	76		68	13		100		0		85	74	100
MSSA only	123		73	52		100		100		89	88	100
Staphylococcus epidermidis	67		48	37		100		29		89	61	100

85-100% Susceptible

60-84% Susceptible

<60% Susceptible

#

Not routinely tested. Historical data suggests frequent susceptibility; confirm with microbiology when relevant

•

Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated

Shaded boxes indicate organism/antimicrobial combines not tested routinely

(a)

Aminoglycoside breakpoints were lowered in 2023 for Enterobacterales and Pseudomonas aeruginosa. Gentamicin should no longer be used for the treatment of Pseudomonas aeruginosa infections.